Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Component-Level Trial Findings CJC-1295 (without DAC, modified GRF 1-29) Phase 1 and Phase 2 work described: Dose-dependent GH elevation (2-10x baseline at studied doses, PMID 16352683) IGF-1 elevation of 1.5-3x baseline at 1-2 weeks Mild facial flushing post-injection in some participants No serious adverse events at studied doses CJC-1295 with DAC The DAC-modified version covalently binds to albumin, extending half-life to 5-8 days (PMID 16352683)
$73.99 $624.99Price range: $73.99 through $624.99 Badger Compounds Research Access This catalog is reserved for qualified research use
Staff is super friendly, and down to earth
In clinical settings, it shows the potential to address symptoms of inflammatory and cardiovascular diseases
The first and most defensible body of work is dermatological and wound-model research in animals
Age of the sermorelin evidence
US$ 22.64
US$ 27.78
US$ 20.18
US$ 26.86
US$ 23.70
US$ 24.29
US$ 27.42
US$ 24.06
US$ 26.04
US$ 25.61
US$ 24.80
US$ 28.33
US$ 20.93
US$ 23.87
US$ 21.29
US$ 24.37
